Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 83,333 shares of Nektar Therapeutics stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $21.54, for a total value of $1,794,992.82. Following the transaction, the chief executive officer now owns 235,837 shares of the company’s stock, valued at approximately $5,079,928.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Nektar Therapeutics (NASDAQ NKTR) opened at 22.27 on Monday. The stock has a 50 day moving average price of $20.29 and a 200 day moving average price of $19.26. Nektar Therapeutics has a 1-year low of $11.41 and a 1-year high of $24.88. The stock’s market cap is $3.48 billion.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.04. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. The business had revenue of $34.60 million for the quarter, compared to analysts’ expectations of $33.64 million. During the same quarter in the prior year, the company posted ($0.36) EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts predict that Nektar Therapeutics will post ($0.94) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/11/nektar-therapeutics-nktr-ceo-sells-1794992-82-in-stock.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Nektar Therapeutics by 0.9% during the 2nd quarter. BlackRock Inc. now owns 20,221,479 shares of the biopharmaceutical company’s stock valued at $395,330,000 after purchasing an additional 185,933 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Nektar Therapeutics by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock valued at $273,893,000 after purchasing an additional 401,914 shares during the last quarter. State Street Corp lifted its holdings in shares of Nektar Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after purchasing an additional 447,023 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Nektar Therapeutics by 0.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock valued at $41,812,000 after purchasing an additional 12,730 shares during the last quarter. Finally, FMR LLC lifted its holdings in shares of Nektar Therapeutics by 42.4% during the 1st quarter. FMR LLC now owns 1,947,644 shares of the biopharmaceutical company’s stock valued at $45,711,000 after purchasing an additional 580,341 shares during the last quarter. Hedge funds and other institutional investors own 95.15% of the company’s stock.

A number of research analysts have issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and set a $23.00 price objective on shares of Nektar Therapeutics in a research note on Friday, July 21st. Zacks Investment Research upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, August 1st. William Blair reiterated an “outperform” rating on shares of Nektar Therapeutics in a research note on Tuesday, July 18th. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Finally, HC Wainwright assumed coverage on Nektar Therapeutics in a research note on Monday, August 7th. They set a “buy” rating and a $31.00 price objective for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and a consensus target price of $26.10.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.